Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2014

View Archived Issues

Novartis reflects on key developments of fourth quarter 2013

Preclinical validation of intranasal delivery of stem cell-based cancer therapeutics

Development of a novel genetic vaccine against viral-mediated respiratory disease

Pfizer reports topline results from PALOMA-1 trial in advanced breast cancer

Edison Pharmaceuticals' EPI-743 receives FDA orphan drug status for Friedreich's ataxia

NeuroPore Therapies begins preclinical development of lead treatment candidate

Cellceutix files trial protocol with FDA for novel antibiotic brilacidin

GSK-2140944 shows efficacy in in vitro and in vivo models of infection

Mitsubishi Tanabe Pharma profiles progress of third quarter of fiscal 2013

Phase II study demonstrates IRX-4204 to be well tolerated in patients with metastatic CRPC

Bayer and German Cancer Research Center form alliance against cancer

Bionor Pharma identifies potential biomarker for Vacc-4x treatment in HIV infection

FDA issues complete response letter for VersaFilm for acute migraine

Rockwell Medical completes phase III program for iron replacement drug Triferic

Euclises Pharmaceuticals presents novel NO-releasing coxibs

Nimbus Discovery patents new IRAK-4 inhibitors

Amarantus BioScience reports phase IIa data for eltoprazine in adult ADHD

Janssen R&D Ireland presents novel TLR7 agonists

Scientists at Bayer Schering Pharma divulge new AKR1C3 inhibitors

Valeant Pharmaceuticals to acquire PreCision Dermatology

Forest Laboratories' acquisition of Aptalis complete

bioTheranostics launches suite of genomic-based tests

Chiesi Farmaceutici acquires Cornerstone Therapeutics

Hawaii Biotech receives NIH grant for anthrax anti-toxin drugs

Sosei and FUJIFILM Pharma sign distribution agreement for Loramyc in Japan

Advanced Cancer Therapeutics launches phase I trial of ACT-PFK-158

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...